Resistance to EGFR-targeted therapy: a family affair.
The EGFR-directed antibody cetuximab has proven, albeit modest, clinical benefit as monotherapy in head and neck and colorectal cancers. In a recent study, Yonesaka et al. uncovered a new mechanism of cetuximab resistance mediated by increased ERBB2 signaling via amplification of ERBB2 or increased levels of the ERBB3/ERBB4 ligand heregulin.
Department of Radiation Oncology, Vanderbilt University, Nashville, TN 37232-2279, USA.
Gregory
G
Vlacich
Robert J
RJ
Coffey